Group Management

The Board of Directors has in accordance with its guidelines and instructions assigned to the Company’s CEO, Tomas Blomquist, to manage the Company’s affaires. The CEO, and the Executive Management under the supervision of the CEO, is responsible for the Group’s day to day business and management. The CEO reports by regular intervals to the Board of Directors how the Company’s business perform, financial result and other issues important to the Company.

Tomas Blomquist

CEO and President

Tomas Blomquist is CEO & President at Biotage as of November 6, 2019. Mr. Blomquist is born in 1970 and has more than 25 years of international experience within the healthcare industry, particularly in the Diagnostics & Medtech area. He has held executive positions at Abbott, Roche, Johnson & Johnson and Analyticon Biotechnologies. Mr. Blomquist has built sustainable high performing organizations and profitable growth companies through direct and indirect sales channels in more than 100 countries. He has extensive expertise in corporate strategy, people development, business model innovation, Internationalization, organizational design and commercialization. Mr. Blomquist is a former middle-distance runner, lives in Stockholm and is passionate to creating value and results to personnel, customers, environment, society and shareholders.

Annette Colin

Chief Financial Officer

Annette Colin is the CFO at Biotage as of April 1st, 2020. Annette is born in 1965 and she has more than 25 years of experience in executive positions as CEO, CFO, COO, Group Financial Controller and Tax Manager, including 14 years in Life Science. Annette has been part of fast-growing companies and organizations and has long experience in building strategic plans, leadership development and streamlining infrastructure. She has been Involved in several M&A and IPO transactions and worked with both Venture Capital and Private Equity owners but the majority in listed companies. Most recent assignments include Annexin Pharmaceuticals AB (publ) Observe Medical International (publ), Stille AB (publ), Lindab International AB (publ), Perbio Science AB (publ) and EY. She has also experience as an investor and from board assignments. Annette has education in Business Administration, marketing, organizational-learn and law at Lund University, Sweden.

Lars Bäckman

Chief Legal Officer

Lars Bäckman has been with Biotage since January 2007 as the VP of Corporate Development. Prior joining Biotage, Lars held the position as SVP of Corporate Development at Affibody. Lars was appointed Chief Legal Officer as of 1 January 2020. He has previous experiences acting as a lawyer at the Swedish law firm Hamilton & Co, specialized in Corporate Finance and Mergers & Acquisitions, and from Venture Management at the Business Development firm Googol. He is a Board member in Chreto A/S. Mr. Bäckman holds a LLM from the Stockholm University and was born in 1961.

About Biotage

Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs approx. 485 people worldwide. The Group had sales of 1,092 MSEK in 2020 and our products are sold in more than 70 countries. Biotage’s share (BIOT) is listed in the Mid Cap segment on the NASDAQ Stockholm.

Ask a specialist

Group Management

Kort om Biotage

Biotage är ett Globalt Impact Tech företag som är djupt engagerade i att lösa samhällsproblem. Vi erbjuder lösningar för kunders arbetsflöden inom forskning och tillverkning av läkemedel, analytisk testning och vatten- och miljöanalyser.

Biotage bidrar till hållbar vetenskap och vi strävar efter att göra världen mer hälsosam, grönare och renare för mänskligheten – HumanKind Unlimited.

Våra kunder spänner över ett brett spektrum av marknadssegment från läkemedel, bioteknik, kontraktsforskning och kontraktstillverkning till kliniska, forensiska och akademiska laboratorier liksom organisationer som fokuserar på livsmedelssäkerhet, rent vatten och miljömässig hållbarhet.

Biotage har huvudkontor i Uppsala, Sverige, och har ca 485 anställda världen över. Koncernen hade en försäljning på 1 092 miljoner kronor 2020 och våra produkter säljs i mer än 70 länder. Biotages aktie (BIOT) är noterad på NASDAQ Stockholm, Mid Cap.

Contact me about

Group Management

SEL-2EV
Two Channel, Extended Collection Bed, UV Detector